drugset
drugset / Trial / NCT03933163

Micronised Resveratrol as a Treatment for Friedreich Ataxia

NCT03933163 ↗

Phase 2 Completed 25 enrolled Murdoch Childrens Research Institute
RandomizedCrossoverQuadruple-blindTreatment

Summary

The aim of this study is to assess the efficacy of micronised resveratrol as a treatment for FRDA, in terms of reducing the severity of ataxia symptoms at 24 weeks, through a randomised blinded, placebo controlled crossover trial.

Timeline

Start
2019-05-23
Primary completion
2024-03-28
Completion
2024-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Resveratrol Small molecule 1 g —

Indications

Friedreich ataxia